Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report - 20/08/22
, G.M.C. Masclee a, A.A. van der Eijk b, C.J. van der Woude a, R.A. de Man a, A.C. de Vries aAbstract |
We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.
Le texte complet de cet article est disponible en PDF.Key words : Hepatitis E, Vedolizumab, IBD, Crohn's disease
Abbreviations : ALT, AMA, ANA, AP, ASMA, AST, CD, CRP, GGT, HEV, IBD, LDH, N, PCR, PT-INR, RNA, TNF-α, UC, WBC
Plan
Vol 46 - N° 7
Article 101948- août 2022 Retour au numéro
Article précédent
- Chaperonin-containing tailless complex polypeptide 1 subunit 6A links with aggravating tumor features and disease-free survival in surgical gastric cancer patients: A long-term follow-up study
- Tingbang He, Deguo Yu, Zhenfeng Wang, Changcai Guo, Yong Chang, Dapeng Wang
- Ciliated hepatic foregut cyst: An uncommon cystic liver lesion
- Emanuel Dias, Hélder Cardoso, João Pacheco, Joanne Lopes, Guilherme Macedo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?